Trials / Completed
CompletedNCT02928978
Ruxolitinib for Premalignant Breast Disease
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Julie Nangia · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.
Conditions
- Ductal Carcinoma In Situ
- Atypical Lobular Hyperplasia
- Atypical Ductal Hyperplasia
- Lobular Carcinoma In Situ
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | tablet (taken by mouth) |
| DRUG | Placebo (for Ruxolitinib) | tablet (taken by mouth) |
Timeline
- Start date
- 2018-05-13
- Primary completion
- 2024-08-29
- Completion
- 2024-09-18
- First posted
- 2016-10-10
- Last updated
- 2026-04-13
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02928978. Inclusion in this directory is not an endorsement.